Catalyst Event
D&D Pharmatech Inc (347850) · Other
From Akros SCHK HK-Korea Biotech Index (ASHKBIO)
6/4/2026, 12:00:00 AM
Announced that three U.S.-based co-founders exercised their stock options and voluntarily placed their entire holdings under a lock-up agreement until May 2027, signaling confidence in the company's long-term growth. Low importance is estimated as voluntary lock-ups typically provide minor positive sentiment, expected.
Korean Translation
미국 공동 창업자 3인이 스톡옵션을 행사했으며, 이들이 보유한 모든 주식에 대해 2027년 5월까지 자발적 보호예수를 설정하여 회사의 장기 성장성에 대한 신뢰를 표명했음을 발표함. 자발적 보호예수는 통상적으로 소폭의 긍정적 심리를 제공하므로 1% 이상의 주가 영향이 예상됨.
Related Recent Events
Samchundang Pharm Co Ltd (000250) · Other
An extraordinary general meeting of shareholders to appoint a new outside director on June 30, 2026, scheduled. Low impact estimated as the appointment of an outside director is a routine administrative matter.
6/30/2026, 12:00:00 AM
Hansoh Pharmaceutical Group Company Limited (3692) · Other
Annual General Meeting on June 26, 2026, to approve 2025 results and dividends. Analysts estimate a 1-5% price impact for this routine corporate event scheduled.
6/26/2026, 12:00:00 AM
United Laboratories International Holdings Ltd (3933) · Other
The Annual General Meeting is scheduled for June 23, 2026, to vote on financial statements and a potential 20% share issuance mandate which could dilute existing shareholdings; high importance due to potential dilution, scheduled.
6/23/2026, 12:00:00 AM
Aimed Bio Inc (0009K0) · Other
Stock price dropped approximately 18% on June 4, 2026, reportedly due to the expiration of a post-IPO lock-up period, which led to a significant volume of shares being sold by institutional investors.
6/4/2026, 12:00:00 AM
Celltrion Inc (068270) · Trading Issue
Bonus issue of 0.05 new shares per common share. The ex-rights date was June 4, 2026, with the new shares scheduled to be listed on June 30, 2026.
6/4/2026, 12:00:00 AM
Innovent Biologics Inc (1801) · Other
Announcement that CLDN18.2 ADC IBI343 (arcotatug tavatecan) met Phase 3 primary endpoint in gastric cancer and NDA was accepted by NMPA; >10% price impact estimated due to first-in-class status expected
6/4/2026, 12:00:00 AM